Potential effect of metformin and vildagliptin against isoniazid induced hepatotoxicity in Wistar albino rats

Background: Metformin and vildagliptin both are anti-diabetic agent and they play an important role in diabetic patients as they reduce blood glucose levels. Studies revealed that both metformin and vildagliptin has the ability to promote beta cell neogenesis and regeneration. So, our study was planned to explore the hepatoprotective potential of metformin and vildagliptin in Wistar albino rats exposed to isoniazid (INH) induced hepatotoxicity. Methods: Wistar albino rats weighing 150-180 g were obtained from Mass Biotech, Chengalpattu, Tamil Nadu. The animals were divided into 6 groups (n=6) and further treated orally against INH-induced hepatotoxicity except normal control group. group 1: normal control, group 2: INH, group 3: metformin+INH, group 4: vildagliptin+INH, group 5: metformin amd vildagliptin+INH, group 6: silymarin. Results: In the present study, INH was administered for 21 days to induce liver damage to rats except normal group. Each group was treated with metformin, vildagliptin, (metformin+vildagliptin) combination and silymarin half an hour before INH challenge. On the 22nd day the blood samples were collected to estimate the AST and ALT levels. Immediately after blood collection the animals were sacrificed, the livers were removed and kept in 10% formalin for histopathological examination. Conclusions: The study found that metformin, vildagliptin, and their combination showed hepatoprotective activity against INH-induced hepatotoxicity. The combination of metformin+vildagliptin was the most effective. Metformin reduces oxidative stress, while vildagliptin balances pro-oxidant and anti-oxidant levels, contributing to their hepatoprotective effects. This suggests their potential usefulness in drug-induced hepatotoxicity.